Viking advances obesity trials and announces new clinical program.
Viking announced its second quarter 2026 financial results with a strong cash position of $502 million. The company reported that the Phase 3 VANQUISH trials for VK2735 are fully enrolled and slated to begin oral Phase 3 trials in the fourth quarter.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day